Clinical Trial: NCT04090710
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Ontario Clinical Oncology Group (OCOG) |
| Information Provided By: | Ontario Clinical Oncology Group (OCOG) |
| Last Update Posted: | 2026-08-28 |
Study Overview
Brief Summary
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
Official Title
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Conditions
Metastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Ipilimumab/ Nivolumab
- Radiation: SBRT + Ipilimumab/Nivolumab
Other Study ID Numbers
- OCOG-2019-CYTOSHRINK
- CA209-7DR
Start Date (Actual)
2020-01-29
Primary Completion Date (Actual)
2026-04-23
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
66
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Ontario Clinical Oncology Group (OCOG) |
| Information Provided By: | Ontario Clinical Oncology Group (OCOG) |
| Last Update Posted: | 2026-08-28 |
Study Overview
Brief Summary
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
Official Title
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Conditions
Metastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Ipilimumab/ Nivolumab
- Radiation: SBRT + Ipilimumab/Nivolumab
Other Study ID Numbers
- OCOG-2019-CYTOSHRINK
- CA209-7DR
Start Date (Actual)
2020-01-29
Primary Completion Date (Actual)
2026-04-23
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
66
Study Type
Interventional
Phase
Phase 2